NICE’s Cost-Effectiveness Range: Should it be Lowered? J. P. Raftery Editorial 09 May 2014 Pages: 613 - 615
Cost-Effectiveness Analysis of Interventions for Tuberculosis Control: DALYs Versus QALYs R. DielN. Lampenius Leading Article 22 May 2014 Pages: 617 - 626
Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease Laura T. BurgersWilliam K. RedekopJohan L. Severens Practical Application 20 April 2014 Pages: 627 - 637
A Review of the Economics of Treating Clostridium difficile Infection Kari A. MergenhagenAmy L. WojciechowskiJoseph A. Paladino Review Article 08 May 2014 Pages: 639 - 650
Cost-Effectiveness Analyses of Targeted Oral Anti-Cancer Drugs: A Systematic Review Fabrice SmieliauskasChun-Ru ChienYa-Chen Tina Shih Systematic Review 13 May 2014 Pages: 651 - 680
Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case Study Pieter DylstArnold VultoSteven Simoens Original Research Article 07 May 2014 Pages: 681 - 691
Mapping EQ-5D Utility Scores from the PedsQL™ Generic Core Scales Kamran A. KhanStavros PetrouSpencer E. Boyle Original Research Article 09 April 2014 Pages: 693 - 706
Cost-Effectiveness Analysis of Docetaxel Versus Weekly Paclitaxel in Adjuvant Treatment of Regional Breast Cancer in New Zealand Rachel Webber-FosterGiorgi KvizhinadzeTony Blakely Original Research Article 24 May 2014 Pages: 707 - 724